New hope for Hard-to-Treat breast cancer: first human trial launches

NCT ID NCT07214662

Recruiting now Disease control Sponsor: Genentech, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 26 times

Summary

This early-stage trial tests a new drug, GDC-0587, in people with advanced ER-positive, HER2-negative breast cancer whose cancer worsened after CDK4/6 inhibitor therapy. The study aims to find safe doses of GDC-0587 given alone or with another drug (giredestrant). About 136 participants will be enrolled to monitor side effects and see if the drug shrinks tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

National Cheng Kung University Hospital
RECRUITING

Tainan, 70403, Taiwan
National Taiwan University Hospital
RECRUITING

Taipei, Taipei City, 10002, Taiwan
START - Midwest - EDOS
RECRUITING

Grand Rapids, Michigan, 49546-7062, United States
START - San Antonio - EDOS
RECRUITING

San Antonio, Texas, 78229-3307, United States

Conditions

Explore the condition pages connected to this study.

BREAST CANCER